基于网络药理学和动物实验探讨克班宁纳米粒治疗非小细胞肺癌的作用机制OA
Mechanism of crebanine nanoparticles in treatment of non-small cell lung cancer based on network pharmacology and animal experiments
目的 基于网络药理学和动物实验探讨克班宁纳米粒(crebanine nanoparticles,Cre-NPs)治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的作用机制.方法 在网络药理学相关数据库中检索克班宁(Cre)与NSCLC的相关靶点,构建"活性成分-交集靶点"和蛋白互作PPI网络图.对交集靶点进行GO富集和KEGG通路富集分析,并对关键靶点进行分子对接.建立M109肺癌皮下荷瘤小鼠模型,分为对照组、模型组、顺铂(2 mg∙kg-1)组、Cre-NPs低、中、高剂量(2、4、6 mg∙kg-1)组.监测小鼠体质量及肿瘤体积变化.计算相对肿瘤增殖率(T/C)、抑瘤率(TGI)、胸腺指数及脾脏指数.血常规及血清生化检测小鼠免疫细胞数和肝肾功能.HE、IHC及TUNEL染色检测肿瘤组织病理变化、Ki67、CD31蛋白表达和细胞凋亡情况.Western blot法检测瘤组织PI3K/Akt/mTOR信号通路及凋亡相关蛋白表达.结果 网络药理学筛选出Cre作用靶点125个,NSCLC疾病靶点1 682个,交集靶点48个.KEGG分析表明PI3K/Akt信号通路可能是Cre抗NSCLC的主要途径,分子对接显示Cre与该通路中的关键蛋白PI3K、Akt、mTOR具有较强的结合力.各给药组的T/C均≤60%,TGI均≥40%,能有效抗肿瘤.与对照组比较,Cre-NPs低、中、高剂量组小鼠的脾脏指数及免疫细胞数明显增加(P<0.05,P<0.01);肝功肾功检测指标变化无统计学意义(P>0.05).与模型组比较,各给药组肿瘤组织均有不同程度的坏死,且 Ki67、CD31蛋白表达降低,细胞凋亡增加.Cre-NPs能降低PI3K、p-PI3K、Akt、p-Akt、mTOR、p-mTOR蛋白的表达(P<0.05,P<0.01),同时降低Bcl-2蛋白的表达(P<0.01),增加Bax、caspase-9、caspase-3(P<0.05,P<0.01)蛋白的表达.结论 Cre-NPs能有效抑制肺癌皮下荷瘤小鼠肿瘤的生长,其作用机制可能与调控PI3K/Akt/mTOR信号通路,促进细胞凋亡有关.
Aim To investigate the Mechanism of cre-banine nanoparticles(Cre-NPs)in treatment of non-small cell lung cancer(NSCLC)based on network pharmacology and animal experiments.Methods The related targets of crebanine(Cre)and NSCLC were searched in the related database of network phar-macology,and the"active ingredient-intersection tar-get"and protein interaction PPI network diagram was constructed.GO enrichment and KEGG pathway en-richment analysis were performed on the intersection targets,and molecular docking was performed on the key targets.The subcutaneous tumor-bearing mouse model of M109 lung cancer was established and di-vided into the control group,model group,cisplatin(2 mg ∙ kg-1)group,and Cre-NPs low,medium and high dose(2,4,6 mg∙kg-1)groups.The changes of body weight and tumor volume in mice were moni-tored.The relative tumor proliferation rate(T/C),tumor inhibition rate(TGI),thymus index and spleen index were calculated.The number of immune cells and liver and kidney function in mice were assessed using blood routine and serum biochemistry.The pathological changes,Ki67,CD31 protein expression and apoptosis of tumor tissues were detected using HE,IHC and TUNEL staining.The expression of PI3K/Akt/mTOR signaling pathway and apoptosis-related proteins in tumor tissues was detected by West-ern blot.Results Network pharmacology screened 125 Cre targets,1 682 NSCLC disease targets,and 48 intersection targets.KEGG analysis showed that PI3K/Akt signaling pathway may be the main pathway of Cre against NSCLC.Molecular docking showed that Cre had a strong binding force with the key proteins PI3K,Akt and mTOR in this pathway.The T/C≤60%and TGI≥40%of each administration group were effective in anti-tumor.Compared with the control group,the spleen index and the number of immune cells in the Cre-NPs low,medium and high dose groups signifi-cantly increased(P<0.05,P<0.01).There was no significant difference in the detection indexes of liver and kidney function(P>0.05).Compared with the model group,the tumor tissue of each administration group had different degrees of necrosis,and the ex-pression of Ki67 and CD31 protein decreased,and the apoptosis increased.Cre-NPs decreased the expres-sion of PI3K,p-PI3K,Akt,p-Akt,mTOR and p-mTOR(P<0.05,P<0.01),decreased the expres-sion of Bcl-2(P<0.01),and increased the expres-sion of Bax,caspase-9 and caspase-3(P<0.05,P<0.01).Conclusions Cre-NPs can effectively inhibit the growth of lung cancer in subcutaneous tumor-bearing mice,and its mechanism may be related to the regulation of PI3K/Akt/mTOR signaling pathway and the promotion of apoptosis.
张海亮;梅佳华;喻锟;薛蕊;袁尉译;杨红云;李宛蓉;李晓飞;程欣
云南中医药大学中药学院||云南省傣医药与彝医药重点实验室云南中医药大学第一临床医学院云南中医药大学中药学院云南中医药大学第一临床医学院云南中医药大学中药学院云南中医药大学中药学院云南中医药大学中药学院云南中医药大学科学技术处云南中医药大学中药学院||云南省傣医药与彝医药重点实验室||云南省高校外用给药系统与制剂技术研究重点实验室,云南 昆明 650500
医药卫生
克班宁纳米粒非小细胞肺癌网络药理学PI3K/Akt/mTOR信号通路细胞凋亡作用机制
crebanine nanoparticlesNSCLCnet-work pharmacologyPI3K/Akt/mTOR signaling path-wayapoptosismechanism of action
《中国药理学通报》 2026 (5)
938-947,10
国家自然科学基金资助项目(No 82560842,82060723)云南省科技厅中医药基础研究联合专项面上项目(No 202501AZ070001-024)云南省科技厅-云南中医药大学应用基础研究联合专项重点项目(No 202001AZ070001-008)国家中医药管理局"十二五"重点学科-傣药学云南省傣医药与彝医药重点实验室开放课题(No 202210SS2206)云南省教育厅科学研究基金项目(No 2024Y345)
评论